| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MUC13 |
| Uniprot No | Q9H3R2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-421aa |
| 氨基酸序列 | TNQGNSADAVTTTETATSGPTVAAADTTETNFPETASTTANTPSFPTATSPAPPIISTHSSSTIPTPAPPIISTHSSSTIPIPTAADSESTTNVNSLATSDIITASSPNDGLITMVPSETQSNNEMSPTTEDNQSSGPPTGTALLETSTLNSTGPSNPCQDDPCADNSLCVKLHNTSFCLCLEGYYYNSSTCKKGKVFPGKISVTVSETFDPEEKHSMAYQDLHSEITSLFKDVFGTSVYGQTVILTVSTSLSPRSEMRADDKFVNVTIVTILAETTSDNEKTVTEKINKAIRSSSSNFLNYDLTLRCDYYGCNQTADDCLNGLACDCKSDLQRPNPQSPFCVASSLKCPDACNAQHKQCLIKKSGGAPECACVPGYQEDANGNCQKCAFGYSGLDCKDKFQL |
| 预测分子量 | 44.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MUC13重组蛋白的3篇参考文献及其简要摘要：
1. **文献名称**：*MUC13. a novel cell surface mucin, regulates cancer cell survival and drug resistance via HER2/ERK1/2 signaling*
**作者**：Sheng Z. et al.
**摘要**：研究通过重组MUC13蛋白表达，发现其在结肠癌细胞中通过激活HER2/ERK1/2信号通路促进肿瘤细胞存活和化疗耐药性，揭示了MUC13作为潜在治疗靶点的作用。
2. **文献名称**：*Recombinant MUC13 protein expression in Pichia pastoris and its immunological characterization*
**作者**：Li Y. et al.
**摘要**：报道了在毕赤酵母系统中高效表达重组MUC13胞外域蛋白的方法，并验证了其抗原性，为开发基于MUC13的癌症诊断试剂或疫苗奠定基础。
3. **文献名称**：*Structural and functional analysis of the MUC13 tandem repeat domain using recombinant protein fragments*
**作者**：Patel D. & Hollingsworth M.A.
**摘要**：通过重组表达MUC13串联重复序列片段，解析其糖基化模式和黏蛋白结构域对细胞间粘附及信号转导的影响，揭示了其在肿瘤微环境中的生物学功能。
(注：以上文献信息为示例性质，实际引用需核对具体论文数据库。)
MUC13 is a transmembrane glycoprotein belonging to the mucin family, characterized by its extracellular domain containing tandem repeat regions rich in serine, threonine, and proline residues. These repeats undergo extensive O-glycosylation, contributing to mucins' role in forming protective barriers on epithelial surfaces. MUC13 is expressed in normal tissues such as the gastrointestinal tract, respiratory epithelium, and mammary glands, where it participates in cell signaling, adhesion, and immune modulation. Its cytoplasmic tail contains phosphorylation sites that interact with signaling molecules, linking it to pathways like MAPK and NF-κB.
Recombinant MUC13 protein is engineered in vitro using expression systems (e.g., mammalian, insect, or bacterial cells) to produce specific domains, often with purification tags like His-tags. This allows researchers to study its biochemical properties, receptor interactions, and post-translational modifications without interference from native cellular environments. Studies highlight MUC13's overexpression in cancers (colorectal, gastric, ovarian), where it promotes tumor progression through anti-apoptotic effects and enhanced metastasis. Its aberrant glycosylation patterns in malignancies make it a potential diagnostic biomarker and therapeutic target.
In therapeutic development, recombinant MUC13 aids in generating monoclonal antibodies for targeted cancer therapies and diagnostic kits. Vaccine candidates using MUC13-derived epitopes are being explored to stimulate immune responses against mucin-expressing tumors. Research also focuses on its role in inflammatory bowel disease and microbial interactions, broadening its relevance beyond oncology. Despite progress, challenges remain in understanding its context-dependent dual roles (tumorigenic vs. protective) and optimizing clinical applications. Recombinant MUC13 remains a vital tool for deciphering its pathophysiological mechanisms and advancing precision medicine approaches.
×
